作为COX-2抑制剂的黄类衍生物的分子对接和动态模拟分析
Pasula Janakiramulu1, Estari Mamidala1
1Department of Zoology, Kakatiya University, Vidyaranyapuri, Warangal, Telangana State 506009 India.
In silico pharmacology
|April 21, 2025
概括
与罗菲科西布相比,库德拉夫拉A作为循环氧化酶-2 (COX-2) 抑制剂的结合亲和力和稳定性优越. 这种黄类化合物为开发新的抗癌和抗炎药物提供了潜力.
科学领域:
- * 计算化学 计算化学
- * 分子药理学分子药理学
- * 医学化学 医学化学
背景情况:
- * 循环氧化酶-2 (COX-2) 与炎症和各种癌症的进展有关.
- * 开发选择性COX-2抑制剂对于治疗干预至关重要.
- * 黄酸是具有潜在药理作用的天然化合物.
研究的目的:
- *使用计算方法评估黄化合物作为COX-2抑制剂的结合潜力和稳定性.
- * 鉴定与现有药物相比,具有更高功效的有力黄类抑制剂.
- * 探索黄和COX-2活性部位之间的分子相互作用.
主要方法:
- *对36种选择的黄化合物进行了分子对接模拟,对抗COX-2酶.
- * 计算了结合亲属性,并分析了与活性部位残留物的关键相互作用.
- *使用GROMACS的分子动力学 (MD) 模拟评估了COX-2-类化合物的稳定性.
主要成果:
- * 库德拉夫甲表现出最高的结合亲和力 (-10.19 kcal/mol),超过了罗菲可西布 (-9.4 kcal/mol).
- * 观察到关键相互作用,包括结合和疏水接触,与关键的COX-2残留物 (Tyr130,Glu465,Arg44).
- *MD模拟表明,COX-2-Cudraflavone A复合物表现出增强的结构稳定性,紧性和减少的灵活性.
结论:
- * 库德拉夫A是一种非常有前途的候选选择性COX-2抑制.
- *这项研究为开发Cudraflavone A作为治疗癌症和炎症疾病的治疗剂提供了强有力的理由.
- * 计算方法在从天然产品库中识别新药候选药物方面是有效的.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
468
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.1K
相关概念视频
Structure-Activity Relationships and Drug Design
437
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
437
The Equilibrium Binding Constant and Binding Strength
12.7K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
12.7K
